metyl-3-O-methylxylopiranoside | 91839-73-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: metyl-3-O-methylxylopiranoside
• 英文别名: methyl 3-O-Me-xylopyranoside；(3R,4S,5R)-2,4-dimethoxyoxane-3,5-diol
• CAS: 91839-73-5
• 化学式: C₇H₁₄O₅
• 分子量: 178.185
• InChiKey: NUIHLOWUOZWYRB-FTFTVQOISA-N

物化性质

• 沸点：
  319.3±42.0 °C(Predicted)
• 密度：
  1.25±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  68.2
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  生成 methyl-2,3,4,6-tetra-O-methyl-D-glucopyranoside 、 metyl-3-O-methylxylopiranoside
  参考文献：
  名称：

  Structures of sarasinosides a1, b1, and c1; New norlanostane-triterpenoid oligoglycosides from the palauan marine sponge Asteropus sarasinosum.

  摘要：

  从帕劳海生海绵 Asteropus sarasinosum 中分离出 9 种新的正羊毛甾烷三萜寡糖苷（sarasinoside），并根据化学性质确定了三种主要寡糖苷的结构，即 sarasinoside A1 (7)、B1 (8) 和 C1 (4)。物理化学证据，包括皂醇的 X 射线分析。

  DOI：

  10.1248/cpb.35.5036

文献信息

• The structures of six antifungal oligoglycosides, stichlorosides A1,A2,B1,B2,C1, and C2, from the sea cucumber Stichopus chloronotus (Brandt).
  作者：ISAO KITAGAWA、MOTOMASA KOBAYASHI、TATSUYA INAMOTO、TOHRU YASUZAWA、YOSHIMASA KYOGOKU

  DOI：10.1248/cpb.29.2387

  日期：——

  Chemical structures are reported for six antifungal lanostane-type triterpene-oligoglycosides from the Okinawan sea cucumber Stichopus chloronotus (BRANDT). The compounds are : stichlorosides A1 (9), B1 (15), C1 (20) [having stichlorogenol (3) as the aglycone] and A2 (10), B2 (16), C 2 (21) [dehydrostichlorogenol (4) as the aglycone].

  来自冲绳海参Stichopus chloronotus（Brandt）的六种抗真菌羊毛甾烷型三萜寡糖苷的化学结构已见报道。这些化合物分别是：stichloroside A1（9）、B1（15）、C1（20）[以stichlorogenol（3）为苷元]，以及A2（10）、B2（16）、C2（21）[以dehydrostichlorogenol（4）为苷元]。
• Pentose derivatives as anti-hyperglycemic drugs
  申请人：Sasson Shlomo

  公开号：US20050277599A1

  公开（公告）日：2005-12-15

  The present invention relates to pentose and pentose derivatives that are effective at increasing glucose transport in a non-insulin dependent manner, and to uses thereof for a) treating and/or preventing hyperglycemia; b) treating and/or preventing the complications of hyperglycemia; c) treating diabetes; d) increasing the rate of cellular glucose transport; e) increasing the rate of cellular glucose uptake; f) improving the ability of a subject to metabolize glucose; g) treating daily blood glucose fluctuations; h) reducing blood sugar levels; i) reducing the dosage of anti-diabetic medication needed for treatment of diabetes. The present invention further provides novel pentose derivatives having beneficial properties in terms of pharmacokinetics, to pharmaceutical compositions comprising these novel compounds and uses thereof.

  本发明涉及以非胰岛素依赖方式有效增加葡萄糖转运的戊糖和戊糖衍生物，并涉及其用于 a) 治疗和/或预防高血糖；b) 治疗和/或预防高血糖并发症；c) 治疗糖尿病；d) 增加细胞葡萄糖转运率； e) 增加细胞葡萄糖摄取率； f) 改善受试者代谢葡萄糖的能力； g) 治疗日常血糖波动； h) 降低血糖水平； i) 减少治疗糖尿病所需的抗糖尿病药物剂量。本发明进一步提供了在药代动力学方面具有有益特性的新型戊糖衍生物，以及包含这些新型化合物的药物组合物及其用途。
• NOVEL PENTOSE DERIVATIVES AS ANTI-HYPERGLYCEMIC DRUGS
  申请人：Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

  公开号：EP1554299B1

  公开（公告）日：2013-01-30
• US7812142B2
  申请人：——

  公开号：US7812142B2

  公开（公告）日：2010-10-12
• [EN] NOVEL PENTOSE DERIVATIVES AS ANTI-HYPERGLYCEMIC DRUGS<br/>[FR] NOUVEAUX DERIVES DE PENTOSES UTILISES EN TANT DE MEDICAMENTS ANTI-HYPERGLYCEMIQUES
  申请人：YISSUM RES DEV CO

  公开号：WO2004034960A2

  公开（公告）日：2004-04-29

  The present invention relates to pentose and pentose derivatives that are effective at increasing glucose transport in a non-insulin dependent manner, and to uses thereof for a) treating and/or preventing hyperglycemia; b) treating and/or preventing the complications of hyperglycemia; c) treating diabetes; d) increasing the rate of cellular glucose transport; e) increasing the rate of cellular glucose uptake; f) improving the ability of a subject to metabolize glucose; g) treating daily blood glucose fluctuations; h) reducing blood sugar levels; i) reducing the dosage of anti-diabetic medication needed for treatment of diabetes. The present invention further provides novel pentose derivatives having beneficial properties in terms of pharmacokinetics, to pharmaceutical compositions comprising these novel compounds and uses thereof.